Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients
NCT: NCT07642882 · RECRUITING
Brief Summary
Repetitive Transcranial Magnetic Stimulation (rTMS) of the motor cortex is a recognized analgesic technique for the treatment of fibromyalgia pain, which represents a largely unmet medical need. However, the effectiveness of motor cortex rTMS is inconsistent, being observed in only about 40% of patients and not always long-lasting. It has been previously shown that predictive factors for a lack of response to motor cortex rTMS include the presence of depressive symptoms, and that prefrontal cortex rTMS is not effective for pain, even though this treatment has proven efficacy in major depressive disorder. The hypothesis is that targeting both the motor and prefrontal cortices with rTMS will yield a particularly beneficial effect in fibromyalgia patients presenting with comorbid depressive symptoms. Given the absence of established biomarkers for predicting rTMS response, an additional aim will be to develop reliable indicators of rTMS efficacy, based on clinical phenotype and measurements of oscillatory patterns assessed by electroencephalogram (EEG) recordings.
Frequently Asked Questions
What is Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients?
Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients is a clinical trial registered under NCT07642882. Current status: RECRUITING.
What is the status of NCT07642882?
The current status of NCT07642882 (Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients) is: RECRUITING.
When did Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients start?
Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients started on 2026-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.